Form 4: MAIA Biotechnology Director Acquires Stock Options

Director Steven M. Chaouki acquired 9,193 stock options in MAIA Biotechnology, Inc. on March 31, 2024.

Summary

• Steven M. Chaouki, a director of MAIA Biotechnology, Inc., reported a transaction involving derivative securities.
• On March 31, 2024, Chaouki acquired 9,193 stock options with an exercise price of $2.20.
• These options, granted under the company's 2021 Equity Incentive Plan, vest immediately and are exercisable from the grant date.
• Following the transaction, Chaouki directly owns 9,193 derivative securities.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing detailing a stock option grant. It's neutral in tone and reflects a routine transaction. The sentiment is moderately positive as it indicates continued alignment of management with shareholder interests.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• Immediate vesting of the options could incentivize the director to contribute to the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.

Stakeholder Impact

• The stock option grant could potentially benefit shareholders if it incentivizes the director to improve company performance.

Key Dates